Page last updated: 2024-12-09

2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about **2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide**. This is a rather specific chemical compound, and it's unlikely to have widespread recognition outside of specialized fields. Here's a breakdown:

**Understanding the Structure**

* **2-(2-bromo-4-methylphenoxy)-:** This part describes a substituted phenol.
* **Phenol:** A benzene ring with an -OH group attached.
* **2-bromo:** A bromine atom attached to the second carbon of the benzene ring.
* **4-methyl:** A methyl group (-CH3) attached to the fourth carbon of the benzene ring.
* **Phenoxy:** The phenol ring with the hydrogen on the -OH group replaced by another atom or group.
* **N-(2-pyridinylmethyl)-:** This part describes a substituted amide.
* **Amide:** A functional group containing a carbonyl group (C=O) connected to a nitrogen atom.
* **N-:** Indicates that the substituted group is directly attached to the nitrogen atom.
* **2-pyridinylmethyl:** A pyridinyl group (a nitrogen-containing aromatic ring) with a methylene group (-CH2-) connecting it to the amide nitrogen.
* **Acetamide:** The simplest amide, containing a methyl group (-CH3) connected to the carbonyl group.

**Putting it Together**

The entire molecule can be visualized as an acetamide with the following modifications:
* The hydrogen attached to the nitrogen is replaced by a 2-pyridinylmethyl group.
* The hydrogen on the carbonyl carbon is replaced by a 2-bromo-4-methylphenoxy group.

**Research Importance**

Without specific context, it's impossible to definitively state why this compound would be important. However, given its structure, it's likely that it has been synthesized or investigated for potential applications in:

* **Pharmaceutical Chemistry:** The combination of a substituted phenol, an amide, and a pyridinyl ring is common in drug molecules. This compound could be a lead compound for developing new drugs, possibly with activity against various targets.
* **Materials Science:** The presence of aromatic rings and a functional amide group suggests potential for use in materials with specific optical or electronic properties.
* **Organic Synthesis:** The compound might be a useful synthetic intermediate or reagent in the preparation of other more complex molecules.

**Finding Information**

To understand the exact research importance of this compound, you would need more information:

* **Where did you encounter this compound?** Was it mentioned in a research paper, patent, or other scientific resource?
* **What is the context?** What specific properties or applications are being studied?

With more information, it would be possible to find relevant research articles, patents, or databases that discuss the compound's significance.

Cross-References

ID SourceID
PubMed CID740886
CHEMBL ID1569325
CHEBI ID114597

Synonyms (16)

Synonym
BIM-0045174.P001
OPREA1_751346
STK091964
2-(2-bromo-4-methylphenoxy)-n-(pyridin-2-ylmethyl)acetamide
CBMICRO_045419
EU-0043793
MLS000109940
smr000105873
CHEBI:114597
AKOS001639193
HMS2324J16
CHEMBL1569325
SR-01000482865-1
sr-01000482865
2-(2-bromo-4-methylphenoxy)-n-(2-pyridinylmethyl)acetamide
Q27196001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency16.94410.007215.758889.3584AID588342
BRCA1Homo sapiens (human)Potency17.78280.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency14.78830.004110.890331.5287AID504466; AID504467
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency4.46680.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency50.11870.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.54810.00798.23321,122.0200AID2546
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.22 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]